Content and quality of 2000 controlled trials in schizophrenia over 50 years - PubMed (original) (raw)
Content and quality of 2000 controlled trials in schizophrenia over 50 years
B Thornley et al. BMJ. 1998.
Abstract
Objective: To provide a comprehensive survey of the content and quality of intervention studies relevant to the treatment of schizophrenia.
Design: Data were extracted from 2000 trials on the Cochrane Schizophrenia Group's register.
Main outcome measures: Type and date of publication, country of origin, language, size of study, treatment setting, participant group, interventions, outcomes, and quality of study.
Results: Hospital based drug trials undertaken in the United States were dominant in the sample (54%). Generally, studies were short (54%<6 weeks), small (mean number of patients 65), and poorly reported (64% had a quality score of <=2 (maximum score 5)). Over 600 different interventions were studied in these trials, and 640 different rating scales were used to measure outcome.
Conclusions: Half a century of studies of limited quality, duration, and clinical utility leave much scope for well planned, conducted, and reported trials. The drug regulatory authorities should stipulate that the results of both explanatory and pragmatic trials are necessary before a compound is given a licence for everyday use.
Figures
Figure
Size of trials (n=1941; 59 studies did not report study size)
Comment in
- Practical problems in recruiting patients with schizophrenia into randomised controlled trials.
Lester H, Wilson S. Lester H, et al. BMJ. 1999 Apr 17;318(7190):1075. doi: 10.1136/bmj.318.7190.1075. BMJ. 1999. PMID: 10205118 Free PMC article. No abstract available.
Similar articles
- Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - Antioxidant treatments for schizophrenia.
Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Magalhães PV, et al. Cochrane Database Syst Rev. 2016 Feb 5;2(2):CD008919. doi: 10.1002/14651858.CD008919.pub2. Cochrane Database Syst Rev. 2016. PMID: 26848926 Free PMC article. Review. - The future of Cochrane Neonatal.
Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834 - Modafinil for people with schizophrenia or related disorders.
Ortiz-Orendain J, Covarrubias-Castillo SA, Vazquez-Alvarez AO, Castiello-de Obeso S, Arias Quiñones GE, Seegers M, Colunga-Lozano LE. Ortiz-Orendain J, et al. Cochrane Database Syst Rev. 2019 Dec 12;12(12):CD008661. doi: 10.1002/14651858.CD008661.pub2. Cochrane Database Syst Rev. 2019. PMID: 31828767 Free PMC article. - Zuclopenthixol dihydrochloride for schizophrenia.
Bryan EJ, Purcell MA, Kumar A. Bryan EJ, et al. Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD005474. doi: 10.1002/14651858.CD005474.pub2. Cochrane Database Syst Rev. 2017. PMID: 29144549 Free PMC article. Review.
Cited by
- Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis.
Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S. Siafis S, et al. Mol Psychiatry. 2023 Aug;28(8):3267-3277. doi: 10.1038/s41380-023-02203-y. Epub 2023 Aug 3. Mol Psychiatry. 2023. PMID: 37537284 Free PMC article. - Uptake of the core outcome set on polycystic ovary syndrome before and after its publication.
Li W, Li G, Chi H, Wang H, Zeng L. Li W, et al. Hum Reprod. 2023 Sep 5;38(9):1816-1824. doi: 10.1093/humrep/dead149. Hum Reprod. 2023. PMID: 37533286 Free PMC article. - Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.
Leucht S, Schneider-Thoma J, Burschinski A, Peter N, Wang D, Dong S, Huhn M, Nikolakopoulou A, Salanti G, Davis JM. Leucht S, et al. World Psychiatry. 2023 Jun;22(2):315-324. doi: 10.1002/wps.21089. World Psychiatry. 2023. PMID: 37159349 Free PMC article. - Quality of reporting of outcomes in trials of therapeutic interventions for pressure ulcers in adults: a protocol for a systematic survey.
Miranda JS, Abbade LPF, Deonizio AP, Abbade JF, Mbuagbaw L, Thabane L. Miranda JS, et al. BMJ Open. 2019 Feb 15;9(2):e024633. doi: 10.1136/bmjopen-2018-024633. BMJ Open. 2019. PMID: 30772853 Free PMC article. - Outcome Selection and Methodological Quality of Major and Minor Shoulder Surgery Studies: A Scoping Review.
El-Boghdadly K, Abdallah FW, Short A, Vorobeichik L, Memtsoudis SG, Chan VWS. El-Boghdadly K, et al. Clin Orthop Relat Res. 2019 Mar;477(3):606-619. doi: 10.1097/CORR.0000000000000578. Clin Orthop Relat Res. 2019. PMID: 30624315 Free PMC article.
References
- Freeman H. The tranquilizing drugs. In: Bellek L, editor. Schizophrenia: a review of the syndrome. New York: Logos; 1958. pp. 473–500.
- Adams CE, Duggan L, Whalbeck K, White P. The Cochrane Schizophrenia Group. Schizophr Res (in press). - PubMed
- Fahey T, Hyde C, Milne R, Thorogood M. The type and quality of randomized controlled trials (RCTs) published in UK public health journals. J Public Health Med. 1995;17:469–474. - PubMed
- Lent V, Langenbach A. A retrospective quality analysis of 102 randomized trials in four leading urological journals from 1984-1989. Urol Res. 1996;24:119–122. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical